Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OMCL vs ZEPP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMCL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

OMCL Overall Winner 6-Pillar Tally: OMCL 3 – 3 ZEPP Matrix Metrics: OMCL 6 – 4 ZEPP

As of Nov 20, 2026, Omnicell Inc (OMCL) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OMCL carries a Unified Composite Score of 45.2/100 (HOLD) at $32.51 (16.2x Forward P/E, 4.6% operating margin), whereas ZEPP carries 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin).

  • Technical & Structure Timing Caution: OMCL is currently in a Breakdown options structure phase (RSI 35.9); meanwhile ZEPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OMCL vs ZEPP
OMCL NASDAQ Head-to-Head Winner
Omnicell Inc
Electronic Computers
$32.51
-2.02% 1D
Market Cap $1.5B
TTM Revenue $1.24B
Forward P/E 16.2x
Beta / 30D Vol 0.92β · 52% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 74.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.9 · SMA20: $35.92 · SMA50: $35.12
ZEPP NYSE
Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
Electronic Computers
$2.31
-8.33% 1D
Market Cap $37.0M
TTM Revenue $276M
Forward P/E 3.1x
Beta / 30D Vol 2.12β · 68% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 63.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.0%), weak momentum, RSI 35
RSI-14: 35.4 · SMA20: $2.40 · SMA50: $3.21

6-Pillar Scorecard Institutional Category Breakdown (OMCL 3 – 3 ZEPP)

Columns: Metric · OMCL · ZEPP
1. Valuation Multiples ZEPP
Forward P/E 16.2x 3.1x
Trailing P/E 34.3x 3.1x
PEG Ratio 15.40x N/M
EV / Revenue 1.1x 0.1x
2. Growth & Scale OMCL
Revenue Growth (YoY) -0.9% +6.9%
Earnings Growth (YoY) +100.1% -68.1%
TTM Revenue (USD) $1.24B $276M
Market Cap $1.5B $37.0M
3. Profitability & Quality OMCL
Gross Margin 44.4% 38.6%
Operating Margin 4.6% -12.6%
Net Profit Margin 3.6% -15.8%
Return on Equity (ROE) 3.5% -21.2%
4. Balance Sheet & Cash Flow OMCL
Cash Generation (TTM) $133M -$30M EBITDA
Cash Flow Margin 10.7% -11.0% EBITDA Mgn
Net Cash / Leverage $114M Net Cash $11.68 Book/Sh · -21.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZEPP
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 41.5% (21st %ile) 124.3% (94th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ZEPP
OpEx & R&D Intensity 39.8% of Rev ($495M) 51.2% of Rev ($141M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Consumer Electronics Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OMCL (6) vs ZEPP (4)
Institutional Metric OMCL ZEPP Criterion Row Edge
Market Capitalization
Scale
$1.5B $37.0M Larger Scale OMCL
Trailing P/E Ratio
Valuation
34.3x 3.1x Lower Multiple ZEPP
Forward P/E Ratio
Valuation
16.2x 3.1x Lower Multiple ZEPP
Revenue Growth (YoY)
Growth
-0.9% +6.9% Higher Growth ZEPP
Operating Margin (TTM)
Profitability
4.6% -12.6% Higher Margin OMCL
Net Profit Margin
Profitability
3.6% -15.8% Higher Margin OMCL
Return on Equity (ROE)
Capital Efficiency
3.5% -21.2% Higher ROE OMCL
52-Week Range Position
Momentum
3% ($32–$55) 0% ($2–$33) Stronger Trend OMCL
Beta / 30D Volatility
Risk Regime
0.92β · 52% Vol 2.12β · 68% Vol Lower Realized Risk OMCL
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 45.7 / 100 (HOLD) Higher Composite ZEPP
Trailing 12M Revenue (USD)
Operating Scale
$1.24B $276M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.4% 38.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
15.40x PEG · 1.1x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$133M ($114M Net Cash) -$30M EBITDA ($11.68 Book/Sh · -21.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OMCL +0.79 pp
OMCL: -12.37% · ZEPP: -13.16%
3M Horizon OMCL +47.51 pp
OMCL: -6.2% · ZEPP: -53.71%
6M Horizon OMCL +46.4 pp
OMCL: -26.8% · ZEPP: -73.2%
1Y Horizon OMCL +84.54 pp
OMCL: -5.85% · ZEPP: -90.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OMCL vs ZEPP. Trailing 12-month operating profitability (OMCL 4.6% vs ZEPP -12.6%) and valuation multiples (OMCL 16.2x vs ZEPP 3.1x Forward P/E) are benchmarked directly in Pillar 4 below.

OMCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.24B
Gross Margin44.4%
Op. Margin4.6%
ROE / Fwd P/E3.5% · 16.2x
ZEPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$276M
Gross Margin38.6%
Op. Margin-12.6%
ROE / Fwd P/E-21.2% · 3.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OMCL BREAKDOWN
144d in phase · OBV DISTRIBUTION
Current IV 41.5%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZEPP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.3%
IV Percentile 94th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZEPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OMCL Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.5B market capitalization and 4.6% operating margin.
OpEx & R&D Reinvestment 39.8% of Rev ($495M)
90D Engineering Disclosures 0 Published
ZEPP Moat Profile Cyclical / Execution-Driven Positioning
Consumer Electronics Operator
Competes within the Consumer Electronics value chain with $37.0M market capitalization and -12.6% operating margin.
OpEx & R&D Reinvestment 51.2% of Rev ($141M)
90D Engineering Disclosures 0 Published

Investor FAQ OMCL vs ZEPP Key Questions & Quantitative Answers

As of Nov 20, 2026, Omnicell Inc (OMCL) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OMCL carries a Unified Composite Score of 45.2/100 (HOLD) at $32.51 (16.2x Forward P/E, 4.6% operating margin), whereas ZEPP carries 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin). Technical & Structure Timing Caution: OMCL is currently in a Breakdown options structure phase (RSI 35.9); meanwhile ZEPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMCL leads the Growth & Scale pillar: OMCL posts -0.9% YoY revenue growth and +100.1% YoY earnings growth on $1.24B TTM revenue (44.4% gross margin, 4.6% operating margin), compared with ZEPP at +6.9% YoY revenue growth and -68.1% YoY earnings growth on $276M TTM revenue (38.6% gross margin, -12.6% operating margin). On trailing 12-month operating scale, OMCL generates $1.24B in USD-normalized revenue versus $276M for ZEPP. In operating R&D and SG&A reinvestment, OMCL deploys 39.8% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 51.2% of Rev ($141M) (0 disclosures) for ZEPP.

ZEPP screens cheaper on headline valuation multiples. OMCL trades at 16.2x Forward P/E, 34.3x Trailing P/E, 15.40x PEG, and 1.1x EV/Revenue (10.7% FCF margin), whereas ZEPP trades at 3.1x Forward P/E, 3.1x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-11.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OMCL (3.5% ROE) versus ZEPP (-21.2% ROE) capital efficiency.

In options market volatility and institutional positioning, OMCL carries 41.5% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.92β · 52% Vol realized risk). By comparison, ZEPP carries 124.3% implied volatility (94th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.12β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.